Should I buy or sell Dr. Reddy's Laboratories stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Dr. Reddy's Laboratories in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" RDY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RDY, but not buy additional shares or sell existing shares. View RDY analyst ratings or view top-rated stocks .

What is Dr. Reddy's Laboratories' stock price target for 2024?

4 brokerages have issued twelve-month target prices for Dr. Reddy's Laboratories' stock. Their RDY share price targets range from $80.00 to $80.00. On average, they expect the company's stock price to reach $80.00 in the next twelve months. This suggests a possible upside of 12.1% from the stock's current price. View analysts price targets for RDY or view top-rated stocks among Wall Street analysts .

How have RDY shares performed in 2024?

Dr. Reddy's Laboratories' stock was trading at $69.58 at the beginning of the year. Since then, RDY shares have increased by 2.6% and is now trading at $71.37. View the best growth stocks for 2024 here .

When is Dr. Reddy's Laboratories' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our RDY earnings forecast .

How were Dr. Reddy's Laboratories' earnings last quarter?

Dr. Reddy's Laboratories Limited (NYSE:RDY) released its quarterly earnings data on Wednesday, January, 31st. The company reported $0.99 EPS for the quarter, topping the consensus estimate of $0.88 by $0.11. The business had revenue of $867 million for the quarter, compared to analysts' expectations of $827.81 million. Dr. Reddy's Laboratories had a net margin of 19.26% and a trailing twelve-month return on equity of 20.97%.

How often does Dr. Reddy's Laboratories pay dividends? What is the dividend yield for Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories declared an annual dividend on Tuesday, July 18th. Stockholders of record on Friday, January 1st will be given a dividend of $0.4877 per share on Friday, July 28th. This represents a yield of 0.7%. The ex-dividend date of this dividend is Friday, July 28th. This is an increase from the stock's previous annual dividend of $0.33. Read our dividend analysis for RDY .

Is Dr. Reddy's Laboratories a good dividend stock?

Dr. Reddy's Laboratories (NYSE:RDY) pays an annual dividend of $0.41 per share and currently has a dividend yield of 0.58%. The company has been increasing its dividend for 4 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 10.82%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, RDY will have a dividend payout ratio of 9.95% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for RDY .

What ETFs hold Dr. Reddy's Laboratories' stock?

ETFs with the largest weight of Dr. Reddy's Laboratories (NYSE:RDY) stock in their portfolio include Putnam PanAgora ESG Emerging Markets Equity ETF (PPEM) , ALPS Emerging Sector Dividend Dogs ETF (EDOG) , First Trust BICK Index Fund (BICK) , Inspire Tactical Balanced ETF (RISN) , Inspire Fidelis Multi Factor ETF (FDLS) , Hartford Multifactor Diversified International ETF (RODE) and Hartford Multifactor Emerging Markets ETF (ROAM) . SPDR Bloomberg SASB Emerging Markets ESG Select ETF (REMG) .

What is G. V. Prasad's approval rating as Dr. Reddy's Laboratories' CEO?

528 employees have rated Dr. Reddy's Laboratories Chief Executive Officer G. V. Prasad on Glassdoor.com . G. V. Prasad has an approval rating of 96% among the company's employees. This puts G. V. Prasad in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Dr. Reddy's Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dr. Reddy's Laboratories investors own include Siemens Aktiengesellschaft (SIEGY) , Tata Motors (TTM) , Infosys (INFY) , HDFC Bank (HDB) , Alibaba Group (BABA) , GSK (GSK) , Merck & Co., Inc. (MRK) , NVIDIA (NVDA) and Pfizer (PFE) .

Who are Dr. Reddy's Laboratories' major shareholders?

Dr. Reddy's Laboratories' stock is owned by a variety of retail and institutional investors. Top institutional investors include Ballentine Partners LLC (0.01%), DGS Capital Management LLC (0.01%), Artemis Investment Management LLP (0.00%), Janiczek Wealth Management LLC (0.00%), Confluence Investment Management LLC (0.00%) and Aprio Wealth Management LLC (0.00%).

How do I buy shares of Dr. Reddy's Laboratories?

Shares of RDY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSE:RDY

Dr. Reddy's Laboratories (RDY) Stock Price, News & Analysis

→ 3 Sub-$10 Stocks to Buy for 2024 (From TradingTips) (Ad)

Free RDY Stock Alerts

$71.37

-0.24 (-0.34%)

(As of 04/17/2024 ET)

Compare

Today's Range: $71.20
▼
$71.71
50-Day Range: $71.17
▼
$77.61
52-Week Range: $53.12
▼
$77.72

Volume: 141,889 shs
Average Volume: 195,413 shs
Market Capitalization: $11.91 billion

P/E Ratio: 18.83
Dividend Yield: 0.57%
Price Target: $80.00

Get Dr. Reddy's Laboratories alerts:

Dr. Reddy's Laboratories MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 12.1% Upside
$80.00 Price Target
Short Interest: Healthy
0.38% of Shares Sold Short
Dividend Strength: Weak
Based on Four Factors
Sustainability: N/A
News Sentiment: 0.00
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 4.04%
From $3.96 to $4.12 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.57 out of 5 stars

Medical Sector

658th out of 913 stocks

Pharmaceutical Preparations Industry

282nd out of 397 stocks

2.0

Analyst's Opinion

Consensus Rating
Dr. Reddy's Laboratories has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 2 hold ratings, and 1 sell rating.
Amount of Analyst Coverage
Dr. Reddy's Laboratories has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.38% of the outstanding shares of Dr. Reddy's Laboratories have been sold short.
Short Interest Ratio / Days to Cover
Dr. Reddy's Laboratories has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Dr. Reddy's Laboratories has recently decreased by 11.77%, indicating that investor sentiment is improving significantly.

1.7

Dividend Strength

Dividend Yield
Dr. Reddy's Laboratories has a dividend yield of 0.58%, which is in the bottom 25% of all stocks that pay dividends.
Dividend Growth
Dr. Reddy's Laboratories has only been increasing its dividend for 4 years.
Dividend Coverage
The dividend payout ratio of Dr. Reddy's Laboratories is 10.82%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Dr. Reddy's Laboratories will have a dividend payout ratio of 9.95% next year. This indicates that Dr. Reddy's Laboratories will be able to sustain or increase its dividend.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for RDY.

0.6

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 2 news articles for Dr. Reddy's Laboratories this week, compared to 2 articles on an average week.
Search Interest
Only 1 people have searched for RDY on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
MarketBeat Follows
4 people have added Dr. Reddy's Laboratories to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Dr. Reddy's Laboratories insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.00% of the stock of Dr. Reddy's Laboratories is held by insiders.
Percentage Held by Institutions
Only 14.02% of the stock of Dr. Reddy's Laboratories is held by institutions.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Dr. Reddy's Laboratories are expected to grow by 4.04% in the coming year, from $3.96 to $4.12 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Dr. Reddy's Laboratories is 18.83, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 139.02.
Price to Earnings Ratio vs. Sector
The P/E ratio of Dr. Reddy's Laboratories is 18.83, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 250.16.
Price to Earnings Growth Ratio
Dr. Reddy's Laboratories has a PEG Ratio of 1.77. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Dr. Reddy's Laboratories has a P/B Ratio of 4.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

This company has increased its dividend every year for 54 years

There are three basic steps to building the Ultimate Dividend Portfolio. Step #1 is to Get The High Yields! So an index fund like the SPY, paying only 1.5% a year, isn’t going to cut it. But a company like Altria Group (MO) will.

Click here to get them (for Free).

About Dr. Reddy's Laboratories Stock (NYSE:RDY)

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

RDY Stock Price History

30 days | 90 days | 365 days | Advanced Chart

RDY Stock News Headlines

April 18, 2024 | americanbankingnews.com

Dr. Reddy's Laboratories Limited to Post FY2026 Earnings of $4.11 Per Share, Zacks Research Forecasts (NYSE:RDY)

March 22, 2024 | finance.yahoo.com

Pharmazz Inc. and Dr. Reddy's Laboratories have entered into a licensing agreement to market Centhaquine (Lyfaquin) as a resuscitative agent for hypovolemic shock in India

April 18, 2024 | DTI (Ad)

Don’t expose yourself to stocks during the week

The S&P 500 just crossed below the 200 day moving average… The Nasdaq is bleeding out… Are we headed for a recession?! If you’ve been in the stock market the last few months, it hasn’t been fun… But what if I told you there was a way to target “BONUS” income just by doing a unique type of trade over the weekend? When the markets are closed. And volatility is minimal.

March 19, 2024 | businesswire.com

Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK

February 24, 2024 | msn.com

Dr. Reddy's Laboratories Limited - Depositary Receipt () (RDY) Price Target Increased by 5.17% to 71.72

February 22, 2024 | msn.com

Global Access to Weight-Loss Treatments: Indian Pharma Giants Eye Affordable Wegovy Alternatives Amid Rising Demand

February 22, 2024 | msn.com

Novo to face Wegovy competition in India as local versions loom: Reuters

February 6, 2024 | ca.finance.yahoo.com

RDY Jun 2024 60.000 call

April 18, 2024 | DTI (Ad)

Don’t expose yourself to stocks during the week

February 1, 2024 | finance.yahoo.com

Dr. Reddy's (RDY) Q3 Earnings and Revenues Surpass Estimates

February 1, 2024 | finance.yahoo.com

Dr. Reddy’s Laboratories Limited (NYSE:RDY) Q3 2024 Earnings Call Transcript

January 31, 2024 | msn.com

Teva hits 52-week high on outlook, API divestment

January 31, 2024 | finance.yahoo.com

UPDATE 1-Indian pharma firm Dr Reddy's beats Q3 profit view on strong US, European businesses

January 31, 2024 | finance.yahoo.com

Dr. Reddy’s Q3 & 9M FY24 Financial Results

January 17, 2024 | msn.com

Indian pharma group Dr Reddy's eyes swoop on Nicotinell

January 11, 2024 | realmoney.thestreet.com

Dr. Reddy's just downgraded at Jefferies, here's why

December 29, 2023 | msn.com

Dr. Reddy's acquires 6.46% stake in Israeli biotech Edity Therapeutics

December 14, 2023 | finance.yahoo.com

Dr. Reddy’s becomes first Indian pharma company to debut on the Dow Jones Sustainability World Index

December 8, 2023 | finance.yahoo.com

Here's Why Doctor Reddy's (RDY) is a Strong Momentum Stock

December 6, 2023 | businesswire.com

Coya Therapeutics, Inc. and Dr. Reddy’s Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination ...

December 6, 2023 | markets.businessinsider.com

Coya Therapeutics, Dr. Reddy's Laboratories Join For Development, Commercialization Of COYA 302

November 20, 2023 | msn.com

Why Doctor Reddy's (RDY) is a Top Momentum Stock for the Long-Term

October 30, 2023 | finance.yahoo.com

Dr. Reddy's (RDY) Q2 Earnings and Revenues Beat Estimates

October 27, 2023 | msn.com

Dr. Reddy's: Continued Q2 Earnings Growth, Supports Long-Term Investment Outlook

October 27, 2023 | finance.yahoo.com

Dr. Reddy’s Q2 FY24 Financial Results

October 26, 2023 | finance.yahoo.com

All You Need to Know About Doctor Reddy's (RDY) Rating Upgrade to Strong Buy

October 11, 2023 | finance.yahoo.com

Here's Why Doctor Reddy's (RDY) is a Strong Growth Stock

See More Headlines

Receive RDY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dr. Reddy's Laboratories and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 1/31/2024
Today: 4/17/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 3/31/2025

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NYSE:RDY
CUSIP: N/A
CIK: 1135951
Web: www.drreddys.com
Phone: 914049002900
Fax: 91-40-4900-2999
Employees: 25,863
Year Founded: 1984

Price Target and Rating

Average Stock Price Target: $80.00
High Stock Price Target: $80.00
Low Stock Price Target: $80.00
Potential Upside/Downside: +12.1%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): $3.79
Trailing P/E Ratio: 18.83
Forward P/E Ratio: 18.02
P/E Growth: 1.77
Net Income: $548 million
Net Margins: 19.26%
Pretax Margin: 25.04%
Return on Equity: 20.97%
Return on Assets: 15.19%

Debt

Debt-to-Equity Ratio: 0.02
Current Ratio: 2.55
Quick Ratio: 1.90

Sales & Book Value

Annual Sales: $2.99 billion
Price / Sales: 3.98
Cash Flow: $4.23 per share
Price / Cash Flow: 16.88
Book Value: $16.87 per share
Price / Book: 4.23

Miscellaneous

Outstanding Shares: 166,880,000
Free Float: 163,540,000
Market Cap: $11.91 billion
Optionable: Optionable
Beta: 0.58

Social Links

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Mr. Gunupati Venkateswara Prasad B.E. (Age 64)
Co-Chairman, MD & Member of Management Council
Comp: $2.25M
Mr. Kallam Satish Reddy B.Tech. (Age 57)
M.S., Chairman of the Board & Member of the Management Council
Comp: $1.38M
Mr. Erez Israeli M.B.A. (Age 56)
CEO & Member of the Management Council
Mr. Parag Agarwal (Age 57)
CFO & Member of Management Council
Mr. Deepak Sapra M.B.A. (Age 49)
CEO of API & Services & Member of Management Council
Mr. Venkata Ramana Motupalli M.B.A. (Age 55)
CEO of Branded Markets - India & Emerging Countries and Member of Management Council
Ms. Archana Bhaskar B.Sc. (Age 57)
M.B.A., EVP, Head of Corporate Communications, Chief Human Resources Officer & Member of Management Council
Mr. Sanjay Sharma B.Tech. (Age 56)
Executive VP, Global Head of Global Manufacturing & Member of Management Council
Mr. Marc Kikuchi B.A. (Age 55)
M.B.A., CEO of North America Generics & Member of Management Council
Mr. Patrick Aghanian B.A. (Age 59)
M.B.A., CEO of European Generics & Member of Management Council

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

RDY Stock Analysis - Frequently Asked Questions

Should I buy or sell Dr. Reddy's Laboratories stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Dr. Reddy's Laboratories in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" RDY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RDY, but not buy additional shares or sell existing shares.
View RDY analyst ratings or view top-rated stocks.
What is Dr. Reddy's Laboratories' stock price target for 2024?: 4 brokerages have issued twelve-month target prices for Dr. Reddy's Laboratories' stock. Their RDY share price targets range from $80.00 to $80.00. On average, they expect the company's stock price to reach $80.00 in the next twelve months. This suggests a possible upside of 12.1% from the stock's current price.
View analysts price targets for RDY or view top-rated stocks among Wall Street analysts.
How have RDY shares performed in 2024?: Dr. Reddy's Laboratories' stock was trading at $69.58 at the beginning of the year. Since then, RDY shares have increased by 2.6% and is now trading at $71.37.
View the best growth stocks for 2024 here.
When is Dr. Reddy's Laboratories' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our RDY earnings forecast.
How were Dr. Reddy's Laboratories' earnings last quarter?: Dr. Reddy's Laboratories Limited (NYSE:RDY) released its quarterly earnings data on Wednesday, January, 31st. The company reported $0.99 EPS for the quarter, topping the consensus estimate of $0.88 by $0.11. The business had revenue of $867 million for the quarter, compared to analysts' expectations of $827.81 million. Dr. Reddy's Laboratories had a net margin of 19.26% and a trailing twelve-month return on equity of 20.97%.
How often does Dr. Reddy's Laboratories pay dividends? What is the dividend yield for Dr. Reddy's Laboratories?: Dr. Reddy's Laboratories declared an annual dividend on Tuesday, July 18th. Stockholders of record on Friday, January 1st will be given a dividend of $0.4877 per share on Friday, July 28th. This represents a yield of 0.7%. The ex-dividend date of this dividend is Friday, July 28th. This is an increase from the stock's previous annual dividend of $0.33.
Read our dividend analysis for RDY.

Is Dr. Reddy's Laboratories a good dividend stock?: Dr. Reddy's Laboratories (NYSE:RDY) pays an annual dividend of $0.41 per share and currently has a dividend yield of 0.58%. The company has been increasing its dividend for 4 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 10.82%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, RDY will have a dividend payout ratio of 9.95% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for RDY.
What ETFs hold Dr. Reddy's Laboratories' stock?: ETFs with the largest weight of Dr. Reddy's Laboratories (NYSE:RDY) stock in their portfolio include Putnam PanAgora ESG Emerging Markets Equity ETF (PPEM), ALPS Emerging Sector Dividend Dogs ETF (EDOG), First Trust BICK Index Fund (BICK), Inspire Tactical Balanced ETF (RISN), Inspire Fidelis Multi Factor ETF (FDLS), Hartford Multifactor Diversified International ETF (RODE) and Hartford Multifactor Emerging Markets ETF (ROAM).SPDR Bloomberg SASB Emerging Markets ESG Select ETF (REMG).
What is G. V. Prasad's approval rating as Dr. Reddy's Laboratories' CEO?: 528 employees have rated Dr. Reddy's Laboratories Chief Executive Officer G. V. Prasad on Glassdoor.com. G. V. Prasad has an approval rating of 96% among the company's employees. This puts G. V. Prasad in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Dr. Reddy's Laboratories own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Dr. Reddy's Laboratories investors own include Siemens Aktiengesellschaft (SIEGY), Tata Motors (TTM), Infosys (INFY), HDFC Bank (HDB), Alibaba Group (BABA), GSK (GSK), Merck & Co., Inc. (MRK), NVIDIA (NVDA) and Pfizer (PFE).
Who are Dr. Reddy's Laboratories' major shareholders?: Dr. Reddy's Laboratories' stock is owned by a variety of retail and institutional investors. Top institutional investors include Ballentine Partners LLC (0.01%), DGS Capital Management LLC (0.01%), Artemis Investment Management LLP (0.00%), Janiczek Wealth Management LLC (0.00%), Confluence Investment Management LLC (0.00%) and Aprio Wealth Management LLC (0.00%).
How do I buy shares of Dr. Reddy's Laboratories?: Shares of RDY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:RDY) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial